A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis

Cancer Genetics and Cytogenetics

Volumn 172, Issue 2, 2007, Pages 107-112

  Larsen, Thomas Stauffer ^a   Hasselbalch, Hans Carl ^a   Pallisgaard, Niels ^a   Kerndrup, Gitte Birk ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; BUSULFAN; HYDROXYUREA; JANUS KINASE 2; PEGINTERFERON;

ADULT; AGED; ARTICLE; CASE REPORT; CHROMOSOME 10P; CHROMOSOME 10Q; CHROMOSOME 18; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CYTOREDUCTIVE SURGERY; DATA ANALYSIS; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; KARYOTYPE; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; SPLENOMEGALY;

AGED; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOFIBROSIS; PHENOTYPE; PHENYLALANINE; POLYCYTHEMIA VERA; TRANSLOCATION, GENETIC; VALINE;

EID: 33845921523     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.09.015     Document Type: Article

References (21)

1. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., and Green A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
2. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., naceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
3. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
4. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Frohling S., Dohner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Gdub T.R., Lee S.J., and Gilliland D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
5. Al-Assar O., Ul-Hassan A., Brown R., Wilson G.A., Hammond D.W., and Reilly J.T. Gains on 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study. Br J Haematol 129 (2005) 66-71
6. Andrieux J.L., and Demory J.L. Karyotype and molecular cytogenetic studies in polycythemia vera. Curr Hematol Rep 4 (2005) 224-229
7. ez-Martin J.L., Graham D.L., Petitt R.M., and Dewald G.W. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 66 (1991) 287-299
8. Reilly J.T. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia. Semin Oncol 32 (2005) 359-364
9. Swolin B., Weinfeld A., and Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 72 (1988) 386-395
10. Reilly J.T., Snowden J.A., Spearing R.L., Fitzgerald P.M., Jones N., Watmore A., and Potter A. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 98 (1997) 96-102
11. Andrieux J., Demory J.L., Caulier M.T., Agape P., Wetterwald M., Bauters F., and Lai J.L. Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet Cytogenet 140 (2003) 118-123
12. Bacher U., Haferlach T., and Schoch C. Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders. Cancer Genet Cytogenet 160 (2005) 179-183
13. Chen Z., Notohamiprodjo M., Guan X.Y., Paietta E., Blackwell S., Stout K., Turner A., Richkind K., Trent J.M., Lamb A., and Sandberg A.A. Gain of 9p in the pathogenesis of polycythemia vera. Genes Chromosomes Cancer 22 (1998) 321-324
14. Pettit J.E., Lewis S.M., and Nicholas A.W. Transitional myeloproliferative disorder. Br J Haematol 43 (1979) 167-184
15. Pedersen RK, Kerndrup GB, Sorensen AG, Mourits-Andersen T, Gram-Hansen P, Pulczynski S, Schmidt KG. Cytogenetic aberrations in adult acute lymphocytic leukemia: optimal technique may influence the results. Cancer Genet Cytogenet;128:7-10.
16. Kerndrup G.B., and Kjeldsen E. Acute leukemia cytogenetics: an evaluation of combining G-band karyotyping with multi-color spectral karyotyping. Cancer Genet Cytogenet 124 (2001) 7-11
17. Vardiman J.W. The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MD. Clin Adv Hematol Oncol 1 (2003) 18, 21
18. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
19. Tefferi A., Lasho T.L., Schwager S.M., Strand J.S., Elliott M., Mesa R., Li C.Y., Wadleigh M., Lee S.J., and Gilliland D.G. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2(V617F) in polycythemia vera. Cancer 106 (2006) 631-635
20. Heiss S., Erdel M., Gunsilius E., Nachbaur D., and Tzankov A. Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Hum Pathol 36 (2005) 1148-1151
21. Bousquet M, Quelen C, De M, V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N, Brousset P. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005;24:7248-52.